Abivax Appoints Ian McGowan
Abivax, a biotechnology company working to develop a functional cure for HIV as well as treatments for inflammatory/autoimmune diseases and cancer, appoints Ian McGowan as Scientific Advisory Board Chair and Juergen Rockstroh as a New Member to the Company's SAB. The changes have been made to support the transition from a discovery-focused biotechnology company to a biopharmaceutical development company.
Dr. McGowan, Professor of Medicine in the Division of Gastroenterology, Hepatology and Nutrition at the University of Pittsburgh School of Medicine and current member of the Scientific Advisory Board, will take over the chairmanship of the Scientific Advisory Board.
Dr. Rockstroh, the current Head of the HIV Outpatient Clinic at the University of Bonn in Germany, will be appointed as a member of the board. Both changes will be enacted at the Scientific Advisory Board’s next meeting at the end of June. Professor Luc Teyton, M.D., Ph. D., Dept. of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA is the current chairman of the Scientific Advisory Board and will continue as a regular member of the SAB.
Ian McGowan trained in Medicine at the University of Liverpool in the United Kingdom. He obtained his PhD in mucosal immunology from the University of Oxford and a second doctoral degree in drug development from the Liverpool School of Tropical Medicine. He is currently Chief Medical Officer at AELIX Therapeutics, a Spanish biotechnology company focused on the development of a therapeutic HIV vaccine and is also Chief Scientific Officer of Orion Biotechnology, a Canadian biotechnology company developing CCR5 antagonists for HIV prevention, oncology, and neuroinflammation.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium